PTJ
SLRN

Paul Tudor Jones’s ACELYRIN SLRN Stock Holding History

Paul Tudor Jones’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48,299
Closed -$152K – 3624
2024
Q4 		$152K Sell
48,299
-92
-0.2% -$445 ﹤0.01% 2879
2024
Q3 		$239K Buy
+48,391
New +$250K ﹤0.01% 2437

Other funds holding SLRN

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Paul Tudor Jones's SLRN Position: Q1 2025 in Review

Paul Tudor Jones sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 48,299 shares — an estimated $152K sold.

Paul Tudor Jones first reported a position in SLRN in Q3 2024 and held it in 2 quarters. The position peaked at $239K in Q3 2024. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Paul Tudor Jones reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 48,299 ACELYRIN shares in Q1 2025, an estimated $152K.
  • Paul Tudor Jones first reported a position in ACELYRIN in Q3 2024 and held it in 2 quarters.
  • Paul Tudor Jones's ACELYRIN position peaked at $239K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Tudor Investment Corp's 13F filing for Q1 2025, filed 15 May 2025.